Arbutus Biopharma Corporation
ABUS
$4.58
$0.173.86%
NASDAQ
| 03/31/2026 | 12/31/2025 | 09/30/2025 | 06/30/2025 | 03/31/2025 | |
|---|---|---|---|---|---|
| Revenue | 179.13M | 1.05M | 529.00K | 10.74M | 1.76M |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | 179.13M | 1.05M | 529.00K | 10.74M | 1.76M |
| Cost of Revenue | 4.12M | 5.01M | 5.78M | 5.50M | 8.96M |
| Gross Profit | 175.01M | -3.96M | -5.25M | 5.24M | -7.20M |
| SG&A Expenses | 5.89M | 3.69M | 3.04M | 3.33M | 5.83M |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 10.01M | 8.70M | 8.82M | 8.83M | 14.79M |
| Operating Income | 169.12M | -7.64M | -8.29M | 1.91M | -13.03M |
| Income Before Tax | 169.70M | -3.76M | -7.74M | 2.52M | -24.53M |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | 169.70M | -3.76M | -7.74M | 2.52M | -24.53M |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | 169.70M | -3.76M | -7.74M | 2.52M | -24.53M |
| EBIT | 169.12M | -7.64M | -8.29M | 1.91M | -13.03M |
| EBITDA | 169.13M | -7.63M | -8.28M | 1.92M | -12.70M |
| EPS Basic | 0.88 | -0.02 | -0.04 | 0.01 | -0.13 |
| Normalized Basic EPS | 0.55 | -0.02 | -0.02 | 0.01 | -0.04 |
| EPS Diluted | 0.87 | -0.02 | -0.04 | 0.01 | -0.13 |
| Normalized Diluted EPS | 0.54 | -0.02 | -0.02 | 0.01 | -0.04 |
| Average Basic Shares Outstanding | 193.77M | 192.35M | 191.78M | 191.55M | 190.71M |
| Average Diluted Shares Outstanding | 195.21M | 192.35M | 191.78M | 192.40M | 190.71M |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |